Geron (NASDAQ:GERN) Stock Price Up 8.5% – What’s Next?

Geron Corporation (NASDAQ:GERN) shares rose 8.5% during mid-day trading on Monday . The stock traded as high as $1.69 and last traded at $1.7150. Approximately 4,567,547 shares changed hands during trading, a decline of 70% from the average daily volume of 15,384,431 shares. The stock had previously closed at $1.58.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on GERN. HC Wainwright reiterated a “neutral” rating on shares of Geron in a report on Tuesday, December 9th. TD Cowen reaffirmed a “buy” rating on shares of Geron in a research report on Thursday, January 29th. UBS Group reiterated a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Geron in a research note on Wednesday, January 28th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $2.17.

Geron Trading Up 6.6%

The company has a 50 day moving average of $1.52 and a 200-day moving average of $1.36. The company has a debt-to-equity ratio of 0.53, a quick ratio of 3.62 and a current ratio of 4.66. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -12.88 and a beta of 0.58.

Geron (NASDAQ:GERN) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.02). The company had revenue of $48.02 million for the quarter, compared to analyst estimates of $50.43 million. Geron had a negative return on equity of 28.86% and a negative net margin of 46.65%. On average, research analysts anticipate that Geron Corporation will post -0.25 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. 55 North Private Wealth LLC acquired a new position in shares of Geron during the 4th quarter worth $29,000. LCM Capital Management Inc raised its holdings in Geron by 80.6% in the 4th quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 10,000 shares during the last quarter. Vistica Wealth Advisors LLC acquired a new position in Geron in the fourth quarter valued at $33,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Geron by 3,307.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 24,410 shares during the last quarter. Finally, Savant Capital LLC boosted its holdings in shares of Geron by 73.8% in the 2nd quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 11,074 shares during the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.